Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Zimberelimab in Metastatic TNBC
NCT05632848Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, zimberelimab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Jun 2022; status: completed.
02
Drugs
tucidinostatzimberelimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05632848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632848.